Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Study to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers

Trial Details

NCT ID
NCT04747054
Phase
PHASE3
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Pembrolizumab
  • Loco-regional radiotherapy
  • Chemotherapy
Locations (sample)
  • Avignon, France|43.94834,4.80892
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046
  • Caen, France|49.18585,-0.35912

Key Eligibility Criteria

  • Patient must have signed a written informed consent form prior to any study specific procedures. When the patient is physically unable to give thei…
  • Histologically confirmed squamous cell carcinoma of head and neck (oral cavity, oropharynx, hypopharynx, and larynx) including unknown primary head…
  • Eligible for treatment by pembrolizumab according to the European Marketing Authorization
  • Patient ≥18 years old

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →